TY - JOUR
T1 - 1,4-Dihydropyridines Active on the SIRT1/AMPK Pathway Ameliorate Skin Repair and Mitochondrial Function and Exhibit Inhibition of Proliferation in Cancer Cells
AU - Valente, Sergio
AU - Mellini, Paolo
AU - Spallotta, Francesco
AU - Carafa, Vincenzo
AU - Nebbioso, Angela
AU - Polletta, Lucia
AU - Carnevale, Ilaria
AU - Saladini, Serena
AU - Trisciuoglio, Daniela
AU - Gabellini, Chiara
AU - Tardugno, Maria
AU - Zwergel, Clemens
AU - Cencioni, Chiara
AU - Atlante, Sandra
AU - Moniot, Sébastien
AU - Steegborn, Clemens
AU - Budriesi, Roberta
AU - Tafani, Marco
AU - Del Bufalo, Donatella
AU - Altucci, Lucia
AU - Gaetano, Carlo
AU - Mai, Antonello
N1 - Publisher Copyright:
© 2015 American Chemical Society.
PY - 2016/2/25
Y1 - 2016/2/25
N2 - Modulators of sirtuins are considered promising therapeutic targets for the treatment of cancer, cardiovascular, metabolic, inflammatory, and neurodegenerative diseases. Here we prepared new 1,4-dihydropyridines (DHPs) bearing changes at the C2/C6, C3/C5, C4, or N1 position. Tested with the SIRTainty procedure, some of them displayed increased SIRT1 activation with respect to the prototype 3a, high NO release in HaCat cells, and ameliorated skin repair in a mouse model of wound healing. In C2C12 myoblasts, two of them improved mitochondrial density and functions. All the effects were reverted by coadministration of compound C (9), an AMPK inhibitor, or of EX-527 (10), a SIRT1 inhibitor, highlighting the involvement of the SIRT1/AMPK pathway in the action of DHPs. Finally, tested in a panel of cancer cells, the water-soluble form of 3a, compound 8, displayed antiproliferative effects in the range of 8-35 μM and increased H4K16 deacetylation, suggesting a possible role for SIRT1 activators in cancer therapy.
AB - Modulators of sirtuins are considered promising therapeutic targets for the treatment of cancer, cardiovascular, metabolic, inflammatory, and neurodegenerative diseases. Here we prepared new 1,4-dihydropyridines (DHPs) bearing changes at the C2/C6, C3/C5, C4, or N1 position. Tested with the SIRTainty procedure, some of them displayed increased SIRT1 activation with respect to the prototype 3a, high NO release in HaCat cells, and ameliorated skin repair in a mouse model of wound healing. In C2C12 myoblasts, two of them improved mitochondrial density and functions. All the effects were reverted by coadministration of compound C (9), an AMPK inhibitor, or of EX-527 (10), a SIRT1 inhibitor, highlighting the involvement of the SIRT1/AMPK pathway in the action of DHPs. Finally, tested in a panel of cancer cells, the water-soluble form of 3a, compound 8, displayed antiproliferative effects in the range of 8-35 μM and increased H4K16 deacetylation, suggesting a possible role for SIRT1 activators in cancer therapy.
UR - http://www.scopus.com/inward/record.url?scp=84959335947&partnerID=8YFLogxK
U2 - 10.1021/acs.jmedchem.5b01117
DO - 10.1021/acs.jmedchem.5b01117
M3 - Artículo
C2 - 26689352
AN - SCOPUS:84959335947
SN - 0022-2623
VL - 59
SP - 1471
EP - 1491
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
IS - 4
ER -